Beam Therapeutics Inc (NASDAQ:BEAM) currently has a daily average trading volume of 1.13M but it saw 1127142 shares traded in last market. With a market cap of 2.37B USD, the company’s current market price of $28.57 came rising about 6.41 while comparing to the previous closing price of $26.85. In past 52 weeks, the stock remained buoying in the range of price level as high as $49.50 and as low as $20.84. In the recent trading on the day, stock has struck highest price mark of $26.23 while lowest mark touched by it was $28.65.
Taking a look at 20-day trading activity of Beam Therapeutics Inc (BEAM) gives us an average price of $26.00, while its current price level is -42.28% below from 52-week high level whereas it is 37.09% above from lowest level seen by the stock during that period. Simple moving average of 50 days or SMA-50 of the stock’s closing price is $26.61 while that of 200 days or SMA-200 reads an average of $25.28. A closer look into the stock’s movement over the week reveals that its volatility is standing at 6.30% during that period while stretching the period over a month that increases to 6.69%. It is also necessary to take a look into other indicators of a stock too, to get a better idea about its price movement. And in doing so, we find stock’s 14-day relative strength index (RSI) standing at 60.49 which implies that the stock is in neutral territory.
Leerink Partners upgraded its recommendation for the stock as a “Outperform” from “Market Perform” on November 06, 2024 while assigning a price target range of $27-$39.
Over the week, BEAM’s stock price is moving 2.70% up while it is 11.86% when we observe its performance for the past one month. Year-to-date it is 15.20% up and over the past year, the stock is showing a downside performance of -1.65%.
The company is expected to be releasing its next quarterly report in March, for which analysts forecasted an EPS of -1.22 while estimate for next year EPS is -4.68. In next quarter, company is expected to be making quarterly sales of $15.15M as analysts are expecting the sales for current fiscal year at $51.42M and seeing the company making $58.9M in sales next year. Moreover, analysts are in estimates of $16.47M for current-quarter revenue.
Currently, Beam Therapeutics Inc’s total number of outstanding shares is 82.56M with 1.51% of that held by the insiders while 93.97% of its common stock has been owned by the institutions. Company’s return on investment (ROI) stands at -15.27% and return on equity (ROE) at -18.29%. Stock’s beta reads 1.91. Stock has a price to book (P/B) ratio of 2.98 while price to sale or P/S ratio amounts to 6.77. Its return on asset (ROA) is -11.67% on average.
